CVD (cardiovascular disease) gender medical technology-access divide feeds Abbott stent trial:
This article was originally published in Clinica
Despite the fact that more women than men die from cardiovascular disease (CVD), women fall far behind men in terms of receiving key medtech-based care. Abbott is citing the fact to explain the reasoning behind a new trial to evaluate its Xience V everolimus-eluting stent system. The Xience V Spirit Women trial was launched last week with its first procedure, performed at the Hospital Italiano, in Buenos Aires, Argentina. Citing data from the American Heart Association and other bodies, it notes that women receive only 33% of angioplasties, stents or bypass surgery, 28% of implantable defibrillators and 36% of open-heart surgery. The trial will involve some 2,000 women at around 100 sites in Europe, the Asia Pacific region, Canada and Latin America, with a five-year follow-up.